Global Partners LP (GLP)

Eli Lilly's explosive growth is driven by GLP-1 drugs Mounjaro and Zepbound, with tirzepatide becoming a historic best-seller in obesity and diabetes. President Trump's aggressive drug pricing reforms...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.

This year has offered no shortage of market-moving headlines shaping investor sentiment. Mixed job reports, new tariffs fueling turbulence in U.S. trade policy, and ongoing uncertainty around Federal ...

NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.

I remain bullish on Hims & Hers Health due to its resilient subscriber growth and strong positioning in the expanding personalized care and telehealth markets. Despite the loss of the GLP-1 contract w...

jetcityimage / iStock Editorial via Getty Images Eli Lilly stock was up more than 50% in 2024, before declining in 2025.

The ongoing compounding/ regulatory headwinds have triggered LLY's and NVO's painful corrections, worsened by the notable market rotation to AI boom. LLY's double beat FQ2'25 performance, raised FY202...

Kelowna, British Columbia –   TheNewswire - August 14, 2025 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, is pleased...